Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Geron Co. stock logo
GERN
Geron
$1.45
+1.0%
$1.38
$1.17
$5.34
$920.35M0.7613.81 million shs16,290 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.38
-0.4%
$1.41
$1.19
$2.04
$1.08B1.423.86 million shs10,894 shs
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
$7.97
+0.3%
$4.85
$0.83
$8.20
$551.93M0.491.42 million shs490 shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$4.27
-1.5%
$4.30
$3.81
$6.75
$254.01M0.69704,947 shs369,547 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Geron Co. stock logo
GERN
Geron
-7.44%-1.38%+3.62%-13.86%-59.72%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+0.36%+9.52%-0.36%-28.13%+0.73%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
+0.13%+0.63%+1.15%+488.15%+246.72%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-2.05%-0.69%-5.91%-10.60%-15.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Geron Co. stock logo
GERN
Geron
2.9945 of 5 stars
3.41.00.01.32.01.70.6
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.4448 of 5 stars
3.42.00.04.42.65.00.6
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
1.749 of 5 stars
2.15.00.00.02.81.70.0
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
4.5107 of 5 stars
3.81.00.04.23.53.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Geron Co. stock logo
GERN
Geron
2.78
Moderate Buy$5.06250.35% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.75100.00% Upside
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
2.29
Hold$8.506.72% Upside
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
3.50
Strong Buy$16.50286.06% Upside

Current Analyst Ratings Breakdown

Latest VNDA, OPK, GERN, and RGLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$13.00
5/13/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
Geron Co. stock logo
GERN
Geron
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.50
5/7/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
5/1/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$9.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$7.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$28.00 ➝ $11.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$8.00 ➝ $7.00
(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Geron Co. stock logo
GERN
Geron
$116.29M7.91N/AN/A$0.46 per share3.14
OPKO Health, Inc. stock logo
OPK
OPKO Health
$689.41M1.58N/AN/A$1.80 per share0.76
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/A$1.05 per shareN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$201.35M1.25N/AN/A$9.23 per share0.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Geron Co. stock logo
GERN
Geron
-$184.13M-$0.21N/AN/AN/A-682.48%-67.53%-45.46%8/14/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$188.86M-$0.07N/AN/AN/A-18.65%-9.76%-6.46%8/6/2025 (Estimated)
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$30.04M-$0.73N/AN/AN/AN/A-53.07%-48.58%8/14/2025 (Estimated)
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$18.90M-$0.75N/AN/AN/A-9.51%-3.49%-2.90%7/30/2025 (Estimated)

Latest VNDA, OPK, GERN, and RGLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$0.29-$0.15+$0.14-$0.15N/AN/A
5/7/2025Q1 2025
Geron Co. stock logo
GERN
Geron
-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 million
5/7/2025Q1 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 million
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
3/20/2025Q4 2024
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$0.20-$0.20N/A-$0.20N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Geron Co. stock logo
GERN
Geron
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Geron Co. stock logo
GERN
Geron
0.04
2.89
2.74
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.30
2.97
2.69
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/A
14.15
14.14
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/A
4.39
4.37

Institutional Ownership

CompanyInstitutional Ownership
Geron Co. stock logo
GERN
Geron
73.71%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
92.38%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
88.14%

Insider Ownership

CompanyInsider Ownership
Geron Co. stock logo
GERN
Geron
7.42%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
4.35%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
10.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Geron Co. stock logo
GERN
Geron
70636.92 million585.76 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
4,200793.05 million359.94 millionOptionable
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
3069.23 million62.65 millionOptionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
29058.93 million53.13 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Geron stock logo

Geron NASDAQ:GERN

$1.44 +0.02 (+1.05%)
As of 09:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.38 -0.01 (-0.36%)
As of 09:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Regulus Therapeutics stock logo

Regulus Therapeutics NASDAQ:RGLS

$7.96 +0.03 (+0.31%)
As of 09:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$4.27 -0.07 (-1.52%)
As of 09:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.